Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
An internal standard for the quantification of glycochenodeoxycholic acid (GCDCA; Item No. 16942) by GC- or LC-MS. GCDCA is a glycine-conjugated form of the primary bile acid chenodeoxycholic acid (Item No. 10011286).1 It reduces formation of cholic acid (Item No. 20250) in primary human hepatocytes when used at a concentration of 100 µM.2 GCDCA (50, 75, and 100 µM) reduces the number of LC3 puncta, a marker of autophagy, and is cytotoxic to L-02 hepatocytes.1 GCDCA (50 µM) induces apoptosis in isolated rat hepatocytes, an effect that can be blocked by the protein kinase C (PKC) inhibitor chelerythrine (Item No. 11314).3 Fecal levels of GCDCA are decreased in a rat model of high-fat diet-induced obesity compared with rats fed a normal diet.4
WARNING This product is not for human or veterinary use.
1. Glycochenodeoxycholic acid impairs transcription factor E3-
2. Feedback regulation of bile acid synthesis in primary human hepatocytes: Evidence that CDCA is the strongest inhibitor. Hepatology 38(4), 930-938 (2003).
3. Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity. Mol. Cell. Biochem. 207(1-2), 19-27 (2000).
4. Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. J. Agric. Food Chem. 67(13), 3624-3632 (2019).
DT-